

Synthetic Studies on Indole Alkaloids. VI¹ Synthesis of Tetrahydroakuammicine and Dihydrocorynantheol via 2-(3-Indolyl)-4-piperidones


Anna Díez,^a Cristina Vila,^a Marie-Eve Sinibaldi,^b Yves Troin,^b and Mario Rubiralta^{a*}


a. Laboratory of Organic Chemistry. Faculty of Pharmacy.
University of Barcelona. 08028-Barcelona, Spain
b. Laboratoire de Chimie des Substances Naturelles, URA CNRS 485.
Université Blaise Pascal. 63177-Aubière Cédex, France

Abstract – The synthesis of dihydrocorynantheol (5) and of the pentacyclic *Strychnos* alkaloid tetrahydroakuammicine (4) is reported from 5-ethyl-*N*-hydroxyethyl-2-(1-phenylsulfonyl-3-indolyl)-4-piperidineacetates (1) by means of a K⁺O⁻Bu/BF₃.Et₂O intramolecular cyclization.

We have reported in previous papers² the usefulness of protected *N*-hydroxyethyl-2-(1-phenylsulfonyl-3-indolyl)-4-piperidones to obtain indolo[2,3-*a*]quinolizidin-2-ones upon treatment with two equivalents of K⁺O⁻Bu. The mechanism of the process implies a displacement of the phenylsulfonyl protecting group and formation of a spiroindolenine intermediate, followed by a BF₃.Et₂O induced transposition of the latter.^{2b,3} More recently, we have applied the method successfully to the formal synthesis of deethylidihydrocorynantheol from methyl *N*-hydroxyethyl-2-(1-phenylsulfonyl-3-indolyl)piperidine-4-acetate.⁴

An additional interest of this approach was due to the fact that the use of three equivalents of K⁺O⁻Bu followed by the action of BF₃.Et₂O could provide an intramolecular cyclization of the ester enolate upon the indolenine iminium salt (Scheme 1), thus opening a remarkably direct route towards *Strychnos* indole alkaloids. We report now the last results obtained from the intramolecular cyclizations of methyl 5-ethyl-1-hydroxyethyl-2-(1-phenylsulfonyl-3-indolyl)-4-piperidineacetates 1.





Reagents and conditions: i) $\text{ICH}_2\text{CH}_2\text{OBn}$ (2 eq), K_2CO_3 (exc.), acetone, Δ , 24 h (67%); ii) (1:1) 4N HCl-MeOH, Δ , 5 h (94%); iii) NaH (1.2 eq), $(\text{EtO})_2\text{POCH}_2\text{COOMe}$ (1.2 eq), DME, 80°C, 4 h (88%); iv) H_2 , 10% Pd-C, EtOH, 56 psi (97%); v) Me_2S (30 eq), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (1.1 eq), CH_2Cl_2 , 30°C, 18 h (83%); vi) tBuO (3 eq), THF, 0°C, 30 min; vii) $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (2 eq), Δ , 30 min (28%).

Scheme 2

Thus, alkylation of piperidine **6** (Scheme 2), prepared according to our general procedure to obtain indolylpiperidone ethylene acetals,⁵ furnished the starting benzyloxyethylpiperidine **7**. Treatment of acetal **7** with 4*N* HCl in MeOH afforded a 1:2.5 mixture of piperidones **8** in 94 % yield. The minor isomer **8a** (*trans*) showed both the indolyl and the ethyl substituents in an equatorial disposition. The conformational preference of the major isomer **8b** (*cis*)^{6,7} was inferred from the multiplicity and the chemical shift, in its ¹H-nmr spectrum, of the signal corresponding to 2-H (a triplet at δ 4.3), which reveals its equatorial disposition *syn* with respect to the nitrogen electron lone pair, and thus an axial orientation of the indolyl substituent. Treatment of **8a** with K₂CO₃ in MeOH at room temperature resulted in a partial reepimerization of the ethyl group furnishing **8b** as the major component of the equilibrium mixture. The major stability of such isomer is related to the tendency of some 2-aryl-4-piperidones to be more stable when the indolyl group is axial.⁸

A Wadsworth-Emmons reaction upon piperidone **8a** resulted in acrylate *E*-**9a** as the major product, accompanied by small proportions of *Z*-**9a** and *E*-**9b** (4:1:1). Similarly, when piperidone **8b** was submitted to the olefination process, the major resulting acrylate was *E*-**9b**, isomers *E*-**9a** and *Z*-**9a** being also detected. These results, were obviously due to the possibility of epimerization in the basic reaction conditions.⁹ Hydrogenation of acrylates **9** furnished satisfactorily the corresponding acetates **10** (a,b) and **11** (a,b),¹⁰ whose debenzoylation was smoothly completed with Me₂S/BF₃.Et₂O,¹¹ thus obtaining aminoalcohols **1** (a,b) and **12** (a,b) in yields over 80%.

At this point we chose to carry out the "K^tOBu/BF₃.Et₂O" reaction on compounds **1**, which presented the appropriate relative stereochemistry for both our purposes. When the reaction was assayed upon a mixture of both C-5 epimers **1** by treatment with 3 equivalents of K^tOBu in our usual reaction conditions (THF, 0°C, 30 min) followed by the addition of the Lewis acid (Scheme 2), a 1:2 mixture of **3**¹² and **4**¹³ was obtained which was separated by flash column chromatography (SiO₂, 9:1 CH₂Cl₂-MeOH). Compound **4** was identified as tetrahydroakuammicine¹⁴ by superposition of its mass spectral data with the previously reported¹⁵ and by comparison of the ¹H- and ¹³C-nmr spectra with the already described ones in the literature for 19,20-dihydroakuammicine.¹⁶ Thus, the most significant signals in the ¹H-nmr were a doublet at δ 4.12 corresponding to the methine H-3 and signals at δ 6.60 and 6.75 for two of the aromatic protons characteristic of the *Strychnos* alkaloids. The epimer on C-3 of compound **3** was also detected, but not that on C-20 of tetrahydroakuammicine (**4**).

These results confirm the usefulness of our synthetic approach towards both *Corynanthe* and *Strychnos* alkaloids, thus fulfilling one of our expected goals¹ to be further developed.

REFERENCES AND NOTES

1. For part III, see: Rubiralta, M.; Diez, A.; Vila, C. *Tetrahedron Lett.*, **1990**, *31*, 3779-3782.
2. (a) Rubiralta, M.; Diez, A.; Vila, C. *Tetrahedron Lett.*, **1990**, *31*, 3347-3350. (b) Rubiralta, M.; Diez, A.; Vila, C.; Troin, Y.; Feliz, M. *J. Org. Chem.*, **1991**, *56*, 6292-6298. (c) Diez, A.; Miguel, D.; Vila, C.; Rubiralta, M.; Remuson, R.; Gelas-Miahle, Y. *Heterocycles*, **1992**, *34*, 13-16.

3. Rubiralta, M.; Diez, A.; Bosch, J.; Solans, X. *J. Org. Chem.*, **1989**, *54*, 5591-5597.
4. Rubiralta, M.; Diez, A.; Vila, C.; Bettiol, J.-L.; Troin, Y.; Sinibaldi, M.-E. *Tetrahedron Lett.*, **1992**, *33*, 1232-1236.
5. Rubiralta, M.; Diez, A.; Balet, A.; Bosch, J. *Tetrahedron*, **1987**, *43*, 3021-3030.
6. All compounds were characterized from their spectral data and elemental analyses.
7. **8b** (major isomer, *cis*, lower Rf) ^1H -nmr (200 MHz) 0.95 (t, $J=7$ Hz, 3H, CH_3), 1.45 and 1.85 (2 m, 1H each, CH_2CH_3), 2.40 (m, 1H, 5-Ha), 2.65 (dd, $J=13$ and 6 Hz, 1H, 3-Ha), 2.82 (t, $J=5$ Hz, 2H, NCH_2), 3.65 (t, $J=5$ Hz, 2H, OCH_2), 4.30 (t, $J=6$ Hz, 1H, 2-He), 4.50 (s, 2H, OCH_2), 7.15 (t, $J=7$ Hz, 1H, Ar-H), 7.25-7.50 (m, 10H), 7.85 (d, $J=7$ Hz, 3H), 8.00 (d, $J=7$ Hz, 1H, In-7H); ^{13}C -nmr 11.7, 21.7, 43.7, 50.5, 52.3, 54.4, 58.5, 69.5, 73.2, 113.7, 121.2, 123.5, 123.8, 124.0, 125.1, 126.6, 126.8, 127.5, 128.3, 129.2, 133.3, 136.0, 138.0, 208.8.
8. Rubiralta, M.; Luque, J.; Orozco, M.; Diez, A. López, I. *Heterocycles*, **1992**, *34*, 449-456.
9. Diez, A.; Tona, M.; Rubiralta, M. *Tetrahedron*, **1990**, *46*, 4393-4406.
10. It is noteworthy that no debenzoylation was ever observed during the hydrogenation step.
11. (a) Fujii, K.; Kawabata, Y.; Fujita, E. *Chem. Pharm. Bull.*, **1980**, *28*, 3662-3664. (b) Bonjoch, J.; Casamitjana, N.; Quirante, J.; Rodriguez, M.; Bosch, J. *J. Org. Chem.*, **1987**, *52*, 267-275.
12. Obtention of **5** (dihydrocorynantheol) was carried out from **3** with LiAlH_4 (4 eq), THF, Δ , 30 min: see, Lounasmaa, M.; Jokela, R.; Tirkkonen, B.; Miettinen, J.; Halonen, M. *Heterocycles*, **1992**, *34*, 321-339.
13. **4**: IR 3400 (NH), 1726 (CO); ^1H -nmr (200 MHz) 0.90 (m, 3H, 18-H), 0.95 and 1.25 (2 m, 1H each, 19-H), 1.7-2.0 (m, 2H, 20-H and 6-H), 2.0-2.6 (m, 6H), 2.7-3.0 (m, 1H, 21-H), 3.1-3.4 (m, 2H, 5-H and 6-H), 3.73 (s, 3H, OCH_3), 4.12 (d, $J=9$ Hz, 1H, 3-H), 6.60 (d, $J=7$ Hz, 1H, 12-H), 6.75 (t, $J=7$ Hz, 1H, 10-H), 7.0-7.2 (m, 2H, 9-H and 12-H); ^{13}C -nmr 11.8 (C-18), 24.8 (C-19), 29.6 (C-14), 30.8 (C-15), 40.5 (C-20), 41.0 (C-6), 50.9 (C-21), 51.8 (OCH_3), 53.4 (C-5), 52.6 (C-16), 54.6 (C-7), 60.8 (C-3), 66.6 (C-2), 109.5 (C-12), 119.1 (C-9), 121.9 (C-10), 128.5 (C-11), 132.0 (C-8), 148.2 (C-12a), 174.8 (C=O); MS (m/z , %) 326 (M^+ , 18), 295 (6), 251 (8), 217 (13), 210 (20), 199 (32), 196 (100), 182 (22), 144 (30), 130 (20), 106 (11).
14. Edwards, P.N.; Smith, G. F. *J. Chem. Soc.*, **1961**, 152-156.
15. Budzikiewicz, H.; Wilson, J. M.; Djerassi, C.; Lévy, J.; LeMen, J.; Janot, M.-M. *Tetrahedron*, **1963**, *19*, 1265-1276.
16. (a) Amat, M.; Linares, A.; Bosch, J. *Tetrahedron Lett.*, **1989**, *30*, 2293-2296. (b) Amat, M.; Linares, A.; Bosch, J. *J. Org. Chem.*, **1990**, *55*, 6299-6312.

Acknowledgements: Support for this research has been provided by the DGICYT (Spain) through grant PB-88-0316 and by the "Acción Integrada Hispano-Francesa" HF-078 (1991) and HF-126B (1992). We also thank the "Departament d'Ensenyament" (Generalitat de Catalunya) for a fellowship given to one of us (C.V.).

(Received in UK 16 November 1992)